Skip to main content
All lobbying clients

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Lobbying client · District of Columbia · filed 2025 to 2026

A trade group representing pharmaceutical research and biotechnology companies.

$73,905,000 Reported spend
161 Filings counted
22 Outside firms hired
128 Bills named

Spend is reported income plus in-house expenses across 161 filings. 3 further filings for this client were restated by a later amendment and are left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 23 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC.

 Who filed for this client 23

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings top 30 of 128
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…
    48 filings
  • S. 832
    EPIC Act of 2025
    32 filings
  • S. 1040
    Drug Competition Enhancement Act
    29 filings
  • S. 1041
    Affordable Prescriptions for Patients Act
    28 filings
  • H.R. 1
    One Big Beautiful Bill Act
    19 filings
  • S. 1097
    Interagency Patent Coordination and Improvement Act of 2025
    19 filings
  • S. 1095
    Stop STALLING Act
    18 filings
  • S. 1096
    Preserve Access to Affordable Generics and Biosimilars Act
    17 filings
  • H.R. 3160
    PREVAIL Act
    12 filings
  • S. 1414
    Expedited Access to Biosimilars Act
    12 filings
  • S. 1553
    PREVAIL Act
    12 filings
  • S. 2658
    Medication Affordability and Patent Integrity Act
    12 filings
  • S. 43
    Skinny Labels, Big Savings Act
    12 filings
  • S. 891
    Bipartisan Health Care Act
    12 filings
  • S. 1954
    Biosimilar Red Tape Elimination Act
    11 filings
  • S. 864
    HELP Copays Act
    11 filings
  • H. Con. Res. 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth…
    10 filings
  • H.R. 3269
    ETHIC Act
    10 filings
  • H.R. 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
    8 filings
  • H.R. 946
    ORPHAN Cures Act
    8 filings
  • S. 2296
    National Defense Authorization Act for Fiscal Year 2026
    8 filings
  • S. 355
    FDA Modernization Act 3.0
    8 filings
  • H.R. 5376
    Share the Savings with Seniors Act
    7 filings
  • H.R. 5378
    Lower Costs, More Transparency Act
    7 filings
  • H.R. 6283
    DRUG Act
    7 filings
  • H.R. 830
    HELP Copays Act
    7 filings
  • S. 1542
    DRUG Act
    7 filings
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
    7 filings
  • H.R. 2214
    DRUG Act
    7 filings
  • H.R. 6485
    Skinny Labels, Big Savings Act
    7 filings
 Reported by year 2 years
  • 2026 $30,805,000 68 filings
  • 2025 $43,100,000 93 filings
 Issues lobbied 9

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 17
  • HOUSE OF REPRESENTATIVES 149
  • SENATE 138
  • Health & Human Services, Dept of (HHS) 35
  • Centers For Medicare and Medicaid Services (CMS) 22
  • Natl Economic Council (NEC) 11
  • Executive Office of the President (EOP) 10
  • Food & Drug Administration (FDA) 10
  • Patent & Trademark Office (PTO) 7
  • Commerce, Dept of (DOC) 6
  • Treasury, Dept of 6
  • Office of Management & Budget (OMB) 3
  • Federal Trade Commission (FTC) 2
  • Labor, Dept of (DOL) 2
  • Government Accountability Office (GAO) 1
  • Justice, Dept of (DOJ) 1
  • President of the U.S. 1
  • U.S. Trade Representative (USTR) 1
 Recent filings 164 total
Q3 report
RADIUS ADVOCACY, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $30,000 income · posted Oct 20, 2026
View →
Q3 report
MARSHALL & POPP, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $40,000 income · posted Oct 20, 2026
View →
Q3 report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $7,040,000 expenses · posted Oct 20, 2026
View →
Q3 report
COVINGTON & BURLING LLP
3rd Quarter 2026 (July 1 - Sep 30) · $340,000 income · posted Oct 20, 2026
View →
Q3 report
DLA PIPER LLP (US)
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2026
View →
Q3 report
AKIN GUMP STRAUSS HAUER & FELD
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $120,000 income · posted Oct 20, 2026
View →
Q3 report
W STRATEGIES, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · $60,000 income · posted Oct 20, 2026
View →
Q3 report
LESIC AND CAMPER COMMUNICATIONS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
MILLER STRATEGIES, LLC
3rd Quarter 2026 (July 1 - Sep 30) · $60,000 income · posted Oct 20, 2026
View →
Q3 report
FARRAGUT PARTNERS LLP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
BGR GOVERNMENT AFFAIRS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
THORN RUN PARTNERS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $40,000 income · posted Oct 20, 2026
View →
Q3 report
SL STRATEGIES, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $45,000 income · posted Oct 20, 2026
View →
Q3 report
THE MCMANUS GROUP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2026
View →
Q3 report
BOSE PUBLIC AFFAIRS GROUP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · posted Oct 20, 2026
View →
Q3 report
EMPIRE CONSULTING GROUP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 19, 2026
View →
Q3 report
BRAVO GROUP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $30,000 income · posted Oct 19, 2026
View →
Q3 report
TODD STRATEGY GROUP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $80,000 income · posted Oct 19, 2026
View →
Q3 report
LMH STRATEGIC SOLUTIONS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $30,000 income · posted Oct 19, 2026
View →
Q3 report
CROSSROADS STRATEGIES, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 17, 2026
View →

Showing the 20 most recent of 164 filings. Search the explorer for "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA".

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem